Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, engages in the discovery and development of novel synthetic DNA- and RNA- based drug candidates. It is developing drug candidates designed to modulate immune responses mediated through Toll-like Receptors (TLRs); and evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA. The company focuses on TLR-targeted clinical candidates for autoimmune and inflammatory diseases and cancer, and on the advancement of its GSO technology platform. Its autoimmune and inflammatory disease program includes IMO-3100, an antagonist of TLR7 and TLR9, a Phase 2 clinical trial for the treatment of psoriasis; and IMO-8400, an antagonist of TLRs 7, 8, and 9, a lead candidate for the treatment of lupus, rheumatoid arthritis, and multiple sclerosis. The company’s cancer program comprises IMO-2055, an agonist of TLR9, a Phase 1b clinical trial for the treatment of cancer. It is also developing GSOs technology platform, which is in preclinical studies for inhibiting in vivo gene expression without requiring a delivery enhancement technology; and TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases, and hematological malignancies, as well as TLR3 agonists for use as vaccine adjuvants. The company has license agreement with Merck KGaA to research, develop, and commercialize products containing its TLR9 agonists for the treatment of cancer; and license and research collaboration agreement with Merck Sharp & Dohme Corp. to research, develop, and commercialize vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer’s disease. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.